von jan » 24.03.2007, 10:04
Hallo Hindemitter,
der (milde) Einfluß von Glivec auf die Haut ist häufig, vor allem in Richtung Ausschlägen, Empfindlichkeit gegen Verletzungen, Hautödemen oder Störung der Pigmentbildung / erhöhte Sonnenempfindlichkeit. Es gibt jedoch ein paar weitere, seltenere und stärkere Nebenwirkungen.
Da ich nicht weiß, wie sich das von Dir genannte Phänomen nennt, zitiere ich jetzt entgegen meinem sonstigen Bemühen der Übersetzung direkt die englischen Fachartikel; vielleicht magst Du Deinen Dermatologen/Hämatologen ja auf die Artikel ansprechen und kannst herausfinden, wie er die Miniflecken medizinisch im Englischen bezeichnen würde? Dann könnten wir gezielter suchen.
Gib uns doch bitte kurz Bescheid, wenn Du was erfährst, interessiert vielleicht noch andere...
Herzliche Grüße
Jan
<!-- BBCode Start --><B>Imatinib mesylate and dermatology part 2: a review of the cutaneous side effects of imatinib mesylate.</B><!-- BBCode End -->
Scheinfeld N.: Department of Dermatology, St. Luke's-Roosevelt Hospital Center, New York, NY 10025, USA. <!-- BBcode auto-mailto start --><a href="mailto:
">
</a><!-- BBCode auto-mailto end -->
Cutaneous reactions to imatinib are common and occur in 9.5% to 69% of patients depending on the series reported. Maculopapular eruptions, erythematous eruptions, edema, and periorbital edema are the most common adverse events observed. Imatinib can also induce severe skin eruptions and generalized skin eruptions. Toxic epidermal necrolysis and Stevens Johnson syndrome has been linked to the use of imatinib. Imatinib has caused acute generalized exanthematous pustulosis. Purpuric vasculitis and mycosis fungoides-like reactions has occurred after imatinib use. Rarer side effects include: hypopigmentation, lichenoid reactions, pityriasiform eruptions, pityriasis rosea, psoriasis, reactivation or induction of porphyria cutanea tarda, neutrophilic eccrine hidradenitis, Sweet's syndrome, erythema nodosum, EBV-positive cutaneous B-cell lymphoproliferative disease, possible induction of squamous cell, hyaline cell syringomas, follicular mucinosis, pseudolymphoma-type drug eruptions, and malpighian epitheliomas. Most cutaneous eruptions caused by imatinib do not necessitate discontinuance of imatinib and are usually self limited, despite continued treatment. Administration of oral or topical corticosteroids can ameliorate some of imatinib's cutaneous side effects.
Quelle: Eur J Haematol. 2005 Feb;74(2):121-3
<!-- BBCode Start --><B>Early and tardive skin adverse events in chronic myeloid leukaemia patients treated with imatinib.</B><!-- BBCode End -->
Breccia M, Carmosino I, Russo E, Morano SG, Latagliata R, Alimena G. Department of Cellular Biotechnology and Hematology, University La Sapienza, Rome, Italy. <!-- BBcode auto-mailto start --><a href="mailto:
">
</a><!-- BBCode auto-mailto end -->
Imatinib related non-haematological side-effects are reported in <10% of chronic myeloid leukaemia patients and include oedema, weight gain, nausea, vomiting and muscle cramps. Cutaneous reactions are well-recognized events occurring mostly in patients treated at doses of 600 mg/d and higher, either in stable or progressive disease. We report on our experience relating to dermatological toxicities in imatinib treated CML patients showing a spectrum of skin reactions ranging from rashes to cutaneous carcinoma.
Quelle: Ann Dermatol Venereol. 2004 Jun-Jul;131(6-7 Pt 1):571-3.
<!-- BBCode Start --><B>Lichenoid cutaneous reaction to imatinib</B><!-- BBCode End -->
Roux C, Boisseau-Garsaud AM, Saint-Cyr I, Helenon R, Quist D, Delaunay C. Service de Dermatologie et Venereologie, CHU La Meynard, Hopital Pierre Zobda Quitman, Fort-de-France, Martinique.
INTRODUCTION: Imatinib (Glivec) is a new therapeutic molecule used for the treatment of chronic myeloid leukemia. Cutaneous side effects with this treatment are common but lichenoid drug eruption is exceptional. We report the first case with profuse cutaneous lichen. CASE REPORT: A 52 year-old woman presented with a 5-year history of chronic myeloid leukemia. The different chemotherapies had failed (persisting polyadenopathies and splenomegalia). She was treated with imatinib (400 mg/day). Two months after the beginning of this treatment a disseminated cutaneous eruption appeared on the trunk, legs, arms and face without mucosal involvement and composed of dark purple, prurigenous, papules suggestive of lichen planus. The cutaneous biopsy confirmed the diagnosis of lichen planus. Suspension of the drug led to the complete regression of the eruption, without any other local treatment, within 2 months. Reintroduction of the drug led to the recurrence of the lesions. DISCUSSION: Cutaneous reactions to imatinib are common and occur in 11 to 67 p. 100 of patients depending on the series. More severe cutaneous reactions have been described: exfoliating dermatites, generalized pustulosis, epidermal necrolysis. The aspect of profuse lichenoid eruption of the skin and the correlation with cutaneous lesions clinically and histologically evocative of lichen planus has not been described other than an isolated buccal involvement in a 72 year-old woman. In our patient, study of the imputability criteria is in favor of imatinib's responsibility.
Quelle: Br J Haematol. 2003 Mar;120(5):911-3
<!-- BBCode Start --><B>Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: A prospective study of 54 patients.</B><!-- BBCode End -->
Valeyrie L, Bastuji-Garin S, Revuz J, Bachot N, Wechsler J, Berthaud P, Tulliez M, Giraudier S. Departments of Dermatology, Public Health, Pathology, and Hematology, Henri-Mondor Hospital (Assistance Publique Hopitaux de Paris), Paris XII University; and Novartis Laboratory, Basel.
BACKGROUND: Imatinib is a new major treatment in chronic myeloid leukemia. OBJECTIVE: To study the cutaneous reactions induced by imatinib. METHODS: All inpatients and outpatients with Philadelphia chromosome-positive leukemia treated by imatinib were included in this prospective study. Clinical features, pathologic findings, evolution of each case, and analysis of potential risk factors were recorded. RESULTS: A total of 54 patients were included, 48 of whom experienced at least 1 cutaneous reaction. These reactions consisted of 36 rashes, 35 edemas, and 22 pruritus. The rash was severe in 5 patients, resulting in temporary interruption of treatment in 3. Highly significant relationships were observed between the daily dose of imatinib and both rashes and edema. In a multivariate analysis, female sex and the daily dose of imatinib were independent risk factors for the development of rashes. CONCLUSION: Adverse cutaneous reactions induced by imatinib are frequent, generally moderate, and dose-dependent.
Quelle: J Am Acad Dermatol 2003 Feb;48(2):201-6
Hallo Hindemitter,
der (milde) Einfluß von Glivec auf die Haut ist häufig, vor allem in Richtung Ausschlägen, Empfindlichkeit gegen Verletzungen, Hautödemen oder Störung der Pigmentbildung / erhöhte Sonnenempfindlichkeit. Es gibt jedoch ein paar weitere, seltenere und stärkere Nebenwirkungen.
Da ich nicht weiß, wie sich das von Dir genannte Phänomen nennt, zitiere ich jetzt entgegen meinem sonstigen Bemühen der Übersetzung direkt die englischen Fachartikel; vielleicht magst Du Deinen Dermatologen/Hämatologen ja auf die Artikel ansprechen und kannst herausfinden, wie er die Miniflecken medizinisch im Englischen bezeichnen würde? Dann könnten wir gezielter suchen.
Gib uns doch bitte kurz Bescheid, wenn Du was erfährst, interessiert vielleicht noch andere...
Herzliche Grüße
Jan
<!-- BBCode Start --><B>Imatinib mesylate and dermatology part 2: a review of the cutaneous side effects of imatinib mesylate.</B><!-- BBCode End -->
Scheinfeld N.: Department of Dermatology, St. Luke's-Roosevelt Hospital Center, New York, NY 10025, USA. <!-- BBcode auto-mailto start --><a href="mailto:
">
</a><!-- BBCode auto-mailto end -->
Cutaneous reactions to imatinib are common and occur in 9.5% to 69% of patients depending on the series reported. Maculopapular eruptions, erythematous eruptions, edema, and periorbital edema are the most common adverse events observed. Imatinib can also induce severe skin eruptions and generalized skin eruptions. Toxic epidermal necrolysis and Stevens Johnson syndrome has been linked to the use of imatinib. Imatinib has caused acute generalized exanthematous pustulosis. Purpuric vasculitis and mycosis fungoides-like reactions has occurred after imatinib use. Rarer side effects include: hypopigmentation, lichenoid reactions, pityriasiform eruptions, pityriasis rosea, psoriasis, reactivation or induction of porphyria cutanea tarda, neutrophilic eccrine hidradenitis, Sweet's syndrome, erythema nodosum, EBV-positive cutaneous B-cell lymphoproliferative disease, possible induction of squamous cell, hyaline cell syringomas, follicular mucinosis, pseudolymphoma-type drug eruptions, and malpighian epitheliomas. Most cutaneous eruptions caused by imatinib do not necessitate discontinuance of imatinib and are usually self limited, despite continued treatment. Administration of oral or topical corticosteroids can ameliorate some of imatinib's cutaneous side effects.
Quelle: Eur J Haematol. 2005 Feb;74(2):121-3
<!-- BBCode Start --><B>Early and tardive skin adverse events in chronic myeloid leukaemia patients treated with imatinib.</B><!-- BBCode End -->
Breccia M, Carmosino I, Russo E, Morano SG, Latagliata R, Alimena G. Department of Cellular Biotechnology and Hematology, University La Sapienza, Rome, Italy. <!-- BBcode auto-mailto start --><a href="mailto:
">
</a><!-- BBCode auto-mailto end -->
Imatinib related non-haematological side-effects are reported in <10% of chronic myeloid leukaemia patients and include oedema, weight gain, nausea, vomiting and muscle cramps. Cutaneous reactions are well-recognized events occurring mostly in patients treated at doses of 600 mg/d and higher, either in stable or progressive disease. We report on our experience relating to dermatological toxicities in imatinib treated CML patients showing a spectrum of skin reactions ranging from rashes to cutaneous carcinoma.
Quelle: Ann Dermatol Venereol. 2004 Jun-Jul;131(6-7 Pt 1):571-3.
<!-- BBCode Start --><B>Lichenoid cutaneous reaction to imatinib</B><!-- BBCode End -->
Roux C, Boisseau-Garsaud AM, Saint-Cyr I, Helenon R, Quist D, Delaunay C. Service de Dermatologie et Venereologie, CHU La Meynard, Hopital Pierre Zobda Quitman, Fort-de-France, Martinique.
INTRODUCTION: Imatinib (Glivec) is a new therapeutic molecule used for the treatment of chronic myeloid leukemia. Cutaneous side effects with this treatment are common but lichenoid drug eruption is exceptional. We report the first case with profuse cutaneous lichen. CASE REPORT: A 52 year-old woman presented with a 5-year history of chronic myeloid leukemia. The different chemotherapies had failed (persisting polyadenopathies and splenomegalia). She was treated with imatinib (400 mg/day). Two months after the beginning of this treatment a disseminated cutaneous eruption appeared on the trunk, legs, arms and face without mucosal involvement and composed of dark purple, prurigenous, papules suggestive of lichen planus. The cutaneous biopsy confirmed the diagnosis of lichen planus. Suspension of the drug led to the complete regression of the eruption, without any other local treatment, within 2 months. Reintroduction of the drug led to the recurrence of the lesions. DISCUSSION: Cutaneous reactions to imatinib are common and occur in 11 to 67 p. 100 of patients depending on the series. More severe cutaneous reactions have been described: exfoliating dermatites, generalized pustulosis, epidermal necrolysis. The aspect of profuse lichenoid eruption of the skin and the correlation with cutaneous lesions clinically and histologically evocative of lichen planus has not been described other than an isolated buccal involvement in a 72 year-old woman. In our patient, study of the imputability criteria is in favor of imatinib's responsibility.
Quelle: Br J Haematol. 2003 Mar;120(5):911-3
<!-- BBCode Start --><B>Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: A prospective study of 54 patients.</B><!-- BBCode End -->
Valeyrie L, Bastuji-Garin S, Revuz J, Bachot N, Wechsler J, Berthaud P, Tulliez M, Giraudier S. Departments of Dermatology, Public Health, Pathology, and Hematology, Henri-Mondor Hospital (Assistance Publique Hopitaux de Paris), Paris XII University; and Novartis Laboratory, Basel.
BACKGROUND: Imatinib is a new major treatment in chronic myeloid leukemia. OBJECTIVE: To study the cutaneous reactions induced by imatinib. METHODS: All inpatients and outpatients with Philadelphia chromosome-positive leukemia treated by imatinib were included in this prospective study. Clinical features, pathologic findings, evolution of each case, and analysis of potential risk factors were recorded. RESULTS: A total of 54 patients were included, 48 of whom experienced at least 1 cutaneous reaction. These reactions consisted of 36 rashes, 35 edemas, and 22 pruritus. The rash was severe in 5 patients, resulting in temporary interruption of treatment in 3. Highly significant relationships were observed between the daily dose of imatinib and both rashes and edema. In a multivariate analysis, female sex and the daily dose of imatinib were independent risk factors for the development of rashes. CONCLUSION: Adverse cutaneous reactions induced by imatinib are frequent, generally moderate, and dose-dependent.
Quelle: J Am Acad Dermatol 2003 Feb;48(2):201-6
